UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $256 to $239.
UBS analyst Ashwani Verma maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and lowers the price target from $256 to $239.